These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 21638088

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 24. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D, Qi W, Zhang P, Zhang Y, Liu Y, Guan H, Wang L.
    Pathol Res Pract; 2018 Feb 01; 214(2):303-307. PubMed ID: 29254799
    [Abstract] [Full Text] [Related]

  • 25. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
    Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C, Guo J, Xue W.
    Pathol Int; 2014 Dec 01; 64(12):601-6. PubMed ID: 25359093
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T, Nakazawa T, Murata S, Kurebayashi J, Ezzat S, Asa SL, Katoh R.
    Hum Pathol; 2007 Dec 01; 38(12):1810-8. PubMed ID: 17714762
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P.
    Pathology; 2014 Oct 01; 46(6):509-17. PubMed ID: 25014730
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X, Wang L, Wang J, Zhao H, Wu J, Liu S, Zhang L, Li Y, Xing X.
    Exp Mol Pathol; 2018 Aug 01; 105(1):153-159. PubMed ID: 30009773
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
    Affolter K, Samowitz W, Tripp S, Bronner MP.
    Genes Chromosomes Cancer; 2013 Aug 01; 52(8):748-52. PubMed ID: 23650027
    [Abstract] [Full Text] [Related]

  • 38. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma.
    Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE.
    Ann Surg Oncol; 2018 Jun 01; 25(6):1775-1781. PubMed ID: 29611028
    [Abstract] [Full Text] [Related]

  • 39. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ, Kong YY, Cai X, Shen XX, Lu YW, Ren M.
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug 08; 46(8):548-552. PubMed ID: 28810295
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.